Treating arterial stiffness in young and elderly patients with the metabolic syndrome

Current Pharmaceutical Design

Volumn 20, Issue 39, 2014, Pages 6106-6113

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^b   Karagiannis, Asterios ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Arterial stiffness; Lifestyle changes; Metabolic syndrome; Statins

Indexed keywords

ATENOLOL; BENDROFLUMETHIAZIDE; BISOPROLOL; CARVEDILOL; CHLORTALIDONE; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEBIVOLOL; PIOGLITAZONE; SITAGLIPTIN; SPIRONOLACTONE; TRIACYLGLYCEROL; VOGLIBOSE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL OBESITY; AGING; ARTERIAL STIFFNESS; ARTICLE; EXERCISE; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; SLEEP DISORDERED BREATHING; WEIGHT REDUCTION; ADULT; AGE; AGED; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; HEALTH BEHAVIOR; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HEALTH BEHAVIOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84911494004     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140417101523     Document Type: Article

References (169)

1. Nelson MR, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc 2010; 85: 460-72.
2. Fernandes VR, Polak JF, Cheng S, et al. Arterial stiffness is associated with regional ventricular systolic and diastolic dysfunction: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 194-201.
3. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-41.
4. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-90.
5. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-70.
6. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-63.
7. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009; 54: 1328-36.
8. Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol 2002; 39: 1005-11.
9. Mitchell GF, Guo CY, Benjamin EJ, et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 2007; 115: 2628-36.
10. Kangas P, Tikkakoski AJ, Tahvanainen AM, et al. Metabolic syndrome may be associated with increased arterial stiffness even in the absence of hypertension: a study in 84 cases and 82 controls. Metabolism 2013; 62: 1114-22.
11. Di Pino A, Alagona C, Piro S, et al. Separate impact of metabolic syndrome and altered glucose tolerance on early markers of vascular injuries. Atherosclerosis 2012; 223: 458-62.
12. Scuteri A, Najjar SS, Orru' M, et al. The central arterial burden of the metabolic syndrome is similar in men and women: the SardiNIA Study. Eur Heart J 2010; 31: 602-13.
13. Lilitkarntakul P, Dhaun N, Melville V, Kerr D, Webb DJ, Goddard J. Risk factors for metabolic syndrome independently predict arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal comorbidity. Diabetes Care 2012; 35: 1774-80.
14. Koivistoinen T, Aatola H, Hutri-Kähönen N, et al. Systemic hemodynamics in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. Ann Med 2010; 42: 612-21.
15. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32.
16. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987-92.
17. Sipila K, Koivistoinen T, Moilanen L, et al. Metabolic syndrome and arterial stiffness: the Health 2000 Survey. Metabolism 2007; 56: 320-6.
18. Koskinen J, Magnussen CG, Viikari JS, et al. Effect of age, gender and cardiovascular risk factors on carotid distensibility during 6-year follow-up. The cardiovascular risk in Young Finns study. Atherosclerosis 2012; 224: 474-9.
19. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
20. Miyaki A, Maeda S, Yoshizawa M, et al. Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology 2009; 60: 351-7.
21. Nordstrand N, Gjevestad E, Hertel JK, et al. Arterial stiffness, lifestyle intervention and a low-calorie diet in morbidly obese pa-tients-a nonrandomized clinical trial. Obesity (Silver Spring) 2013; 21: 690-7.
22. Keogh JB, Brinkworth GD, Noakes M, Belobrajdic DP, Buckley JD, Clifton PM. Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. Am J Clin Nutr 2008; 87: 567-76.
23. Hummel SL, Seymour EM, Brook RD, et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 2012; 60: 1200-6.
24. O'Donovan C, Lithander FE, Raftery T, Gormley J, Mahmud A, Hussey J. Inverse Relationship Between Physical Activity and Arterial Stiffness in Adults with Hypertension. J Phys Act Health 2014; 11: 272-7.
25. Jae SY, Heffernan KS, Fernhall B, et al. Association between cardiorespiratory fitness and arterial stiffness in men with the metabolic syndrome. Diabetes Res Clin Pract 2010; 90: 326-32.
26. Eleuterio-Silva MA, Sá da Fonseca LJ, Velloso EP, et al. Shortterm cardiovascular physical programme ameliorates arterial stiffness and decreases oxidative stress in women with metabolic syndrome. J Rehabil Med 2013; 45: 572-9.
27. Hill AM, Buckley JD, Murphy KJ, Howe PR. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 2007; 85: 1267-74.
28. Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Shortterm aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Diabetes Care 2009; 32: 1531-5.
29. Yang SJ, Hong HC, Choi HY, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fe-tuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 2011; 75: 464-9.
30. Beck DT, Martin JS, Casey DP, Braith RW. Exercise training reduces peripheral arterial stiffness and myocardial oxygen demand in young prehypertensive subjects. Am J Hypertens 2013; 26: 1093-102.
31. Iguchi A, Yamakage H, Tochiya M, et al. Effects of Weight Reduction Therapy on Obstructive Sleep Apnea Syndrome and Arterial Stiffness in Patients with Obesity and Metabolic Syndrome. J Atheroscler Thromb 2013; 20: 807-20.
32. Satoh-Asahara N, Suganami T, Majima T, et al. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome. Clin J Am Soc Nephrol 2011; 6: 265-73.
33. Satoh N, Shimatsu A, Kato Y, et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens Res 2008; 31: 1921-30.
34. Pietri P, Vlachopoulos C, Vyssoulis G, Ioakeimidis N, Stefanadis C. Macro-and microvascular alterations in patients with metabolic syndrome: sugar makes the difference. Hypertens Res 2013 Oct 31. [Epub ahead of print].
35. Weng C, Yuan H, Yang K, et al. Gender-specific association between the metabolic syndrome and arterial stiffness in 8, 300 subjects. Am J Med Sci 2013; 346: 289-94.
36. Seo HS, Kang TS, Park S, et al. Insulin resistance is associated with arterial stiffness in nondiabetic hypertensives independent of metabolic status. Hypertens Res 2005; 28: 945-51.
37. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hy-perglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia-betologia 2012; 55: 1577-96.
38. Kiyici S, Ersoy C, Kaderli A, et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 2009; 86: 44-50.
39. Araki T, Emoto M, Teramura M, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pio-glitazone and metformin. Metabolism 2006; 55: 996-1001.
40. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol 2012; 11: 61.
41. Caballería L, Pera G, Rodríguez L, Auladell MA, Bernad J, Canut S, Torán P. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol 2012; 24: 1007-11.
42. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
43. Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hy-pertens 2010; 28: 1699-707.
44. Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-72.
45. Sung SH, Chuang SY, Sheu WH, Lee WJ, Chou P, Chen CH. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population. Am J Cardiol 2009; 103: 1411-6.
46. Ohashi N, Ito C, Fujikawa R, Yamamoto H, Kihara Y, Kohno N. The impact of visceral adipose tissue and high-molecular weight adiponectin on cardio-ankle vascular index in asymptomatic Japanese subjects. Metabolism 2009; 58: 1023-9.
47. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mik-hailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
48. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010; 95: 722-30.
49. Kaya MG, Calapkorur B, Karaca Z, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 77: 885-92.
50. Soares GM, Vieira CS, Martins WP, et al. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol (Oxf) 2009; 71: 406-11.
51. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008; 23: 2352-8.
52. Panidis D, Macut D, Tziomalos K, et al. Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013; 78: 586-92.
53. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30: 471-8.
54. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract 2010; 64: 1796-801.
55. Yeo HY, Kim OY, Lim HH, Kim JY, Lee JH. Association of serum lycopene and brachial-ankle pulse wave velocity with metabolic syndrome. Metabolism 2011; 60: 537-43.
56. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics Other Than the Diagnostic Criteria Associated with Metabolic Syndrome: an Overview. Curr Vasc Pharmacol 2013 Apr 25. [Epub ahead of print].
57. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007; 12: 311-8.
58. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-6.
59. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14: 561-7.
60. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007; 194: e123-30.
61. Oz O, Tuncel E, Eryilmaz S, et al. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine 2008; 33: 101-5.
62. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012; 29: 1115-8.
63. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Järvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999; 48: 821-7.
64. Ohira M, Endo K, Oyama T, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011; 60: 78-85.
65. Williams B. Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity--mortality. J Hypertens 2012; 30 Suppl: S13-8.
66. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012; 12: 143-56.
67. Radchenko GD, Sirenko YM, Kushnir SM, Torbas OO, Dobrokhod AS. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with mod erate-to-severe hypertension: results of the 6-month ELIZA trial. Vasc Health Risk Manag 2013; 9: 535-49.
68. Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014; 8: 74-82.
69. Shah NK, Smith SM, Nichols WW, et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich) 2011; 13: 917-24.
70. Briasoulis A, Oliva R, Kalaitzidis R, et al. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich) 2013; 15: 473-9.
71. Vitale C, Marazzi G, Iellamo F, et al. Effects of nebivolol or irbe-sartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Ne-bivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol 2012; 155: 279-84.
72. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54: 716-23.
73. Ishimitsu T, Ohno E, Nakano N, et al. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 2011; 33: 366-72.
74. Mahmud A, Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002; 15: 1092-5.
75. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002; 20: 2423-8.
76. Al Badarin FJ, Abuannadi MA, Lavie CJ, O'Keefe JH. Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. Am J Cardiol 2011; 107: 1178-84.
77. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslip-idemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J 2011; 5: 85-9.
78. Alem M, Milia P, Muir S, Lees K, Walters M. Comparison of the effects of diuretics on blood pressure and arterial stiffness in patients with stroke. J Stroke Cerebrovasc Dis 2008; 17: 373-7.
79. Jiang XJ, O'Rourke MF, Zhang YQ, He XY, Liu LS. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007; 25: 1095-9.
80. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57: 689-94.
81. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110-7.
82. Tziomalos K, Athyros VG, Mikhailidis DP, Karagiannis A. Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension. Curr Pharm Des 2013; 19: 3766-72.
83. Kwon BJ, Jang SW, Choi KY, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res 2013; 36: 79-84.
84. Tziomalos K, Kirkineska L, Baltatzi M, et al. Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome. Blood Press 2013; 22: 307-11.
85. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-52.
86. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-26.
87. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18: 50-5.
88. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist am-lodipine in systolic hypertension. Hypertension 2003; 41: 1021-6.
89. Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc 2010; 58: 1327-32.
90. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-904.
91. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
92. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-5.
93. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007; 20: 184-9.
94. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M. Effects of am-lodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006; 20: 787-94.
95. Hayoz D, Zappe DH, Meyer MA, et al. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. J Clin Hypertens (Greenwich) 2012; 14: 773-8.
96. Tomiyama H, Yoshida M, Yamada J, et al. Arterial-cardiac destiff-ening following long-term antihypertensive treatment. Am J Hyper-tens 2011; 24: 1080-6.
97. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009; 16: 621-6.
98. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
99. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26: 608-16.
100. Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-72.
101. Sadat U, Howarth SP, Usman A, et al. Effect of low-and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging-a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study. J Atheroscler Thromb 2013; 20: 46-56.
102. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11: 1143-60.
103. Pirro M, Schillaci G, Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2007; 17: 436-41.
104. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 2009; 54: 763-8.
105. Hongo M, Kumazaki S, Izawa A, et al. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J 2011; 75: 2660-7.
106. Wang J, Xu J, Zhou C, et al. Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy. J Clin Hypertens (Greenwich) 2012; 14: 245-9.
107. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mik-hailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009; 15: 479-89.
108. Weiss TW, Arnesen H, Seljeflot I. Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism 2013; 62: 1008-13.
109. Scuteri A, Orru M, Morrell C, et al. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA Study. Atherosclerosis 2011; 215: 459-64.
110. Oh EG, Kim SH, Bang SY, et al. High-sensitivity C-reactive protein is independently associated with arterial stiffness in women with metabolic syndrome. J Cardiovasc Nurs 2012; 27: 61-7.
111. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-71.
112. Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9: 647-57.
113. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
114. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
115. Deedwania P, Barter P, Carmena R, et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-28.
116. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11: 1965-70.
117. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010; 8: 632-7.
118. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168: 1531-40.
119. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Cole-sevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 1479-84.
120. Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5: 16-7.
121. Tziomalos K, Karagiannis A, Mikhailidis DP, Athyros VG. Cole-sevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013; 19: 3115-23.
122. Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010; 17: 1070-6.
123. Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011; 18: 1080-9.
124. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Go-lik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007; 63: 113-21.
125. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
126. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
127. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER nia-cin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.
128. Wang G, He L, Liu J, et al. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther 2013; 31: 161-7.
129. Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 2190-7.
130. Hongo M, Tsutsui H, Mawatari E, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipi-demia: a 5-year follow-up study. Circ J 2008; 72: 722-8.
131. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007; 49: 776-85.
132. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapen-taenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hyper-tens Res 2009; 32: 1004-8.
133. McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1994; 14: 1425-9.
134. Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007; 191: 162-7.
135. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF. Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet. J Nutr 2013; 143: 437-41.
136. Satoh-Asahara N, Shimatsu A, Sasaki Y, et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012; 35: 2631-9.
137. Sjoberg NJ, Milte CM, Buckley JD, Howe PR, Coates AM, Saint DA. Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation. Br J Nutr 2010; 103: 243-8.
138. Wang S, Ma AQ, Song SW, Quan QH, Zhao XF, Zheng XH. Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. Eur J Clin Nutr 2008; 62: 1426-31.
139. Takaki A, Umemoto S, Ono K, et al. ELIA study group. Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study. J Atheroscler Thromb 2011; 18: 857-66.
140. Tziomalos K, Athyros VG, Mikhailidis DP. Fish oils and vascular disease prevention: an update. Curr Med Chem 2007; 14: 2622-8.
141. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 2012; 53: 2429-35.
142. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013; 62: 569-76.
143. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.
144. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-8.
145. Tomiyama H, Takata Y, Shiina K, et al. Concomitant existence and interaction of cardiovascular abnormalities in obstructive sleep apnea subjects with normal clinic blood pressure. Hypertens Res 2009; 32: 201-6.
146. Litvin AY, Sukmarova ZN, Elfimova EM, et al. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag 2013; 9: 229-35.
147. Buchner NJ, Quack I, Stegbauer J, Woznowski M, Kaufmann A, Rump LC. Treatment of obstructive sleep apnea reduces arterial stiffness. Sleep Breath 2012; 16: 123-33.
148. Kohler M, Pepperell JC, Casadei B, et al. CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J 2008; 32: 1488-96.
149. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tka-cova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-92.
150. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts 2013; 6: 449-68.
151. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-61.
152. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52.
153. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-37.
154. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev 2011; 12: 515-24.
155. Iancu ME, Copàescu C, Serban M, Ginghinà C. Favorable Changes in Arterial Elasticity, Left Ventricular Mass, and Diastolic Function After Significant Weight Loss Following Laparoscopic Sleeve Gastrectomy in Obese Individuals. Obes Surg 2014; 24: 364-70.
156. Samaras K, Viardot A, Lee PN, et al. Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: the role of immune cell activation and insulin resistance. Diab Vasc Dis Res 2013; 10: 40-8.
157. Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257-62.
158. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-36.
159. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010; 26: 713-9.
160. Simkova A, Bulas J, Balogova S, Reptova A, Kisa B, Luha J, Ki-nova S. Metabolic syndrome and its effect on aortic stiffness in premenopausal women. Bratisl Lek Listy 2013; 114: 279-82.
161. Iannuzzi A, Licenziati MR, Acampora C, et al. Carotid artery stiffness in obese children with the metabolic syndrome. Am J Cardiol 2006; 97: 528-31.
162. Xi B, Zhang L, Mi J. Reduced arterial compliance associated with metabolic syndrome in Chinese children and adolescents. Biomed Environ Sci 2010; 23: 102-7.
163. Koivistoinen T, Hutri-Kähönen N, Juonala M, et al. Metabolic syndrome in childhood and increased arterial stiffness in adulthood: the Cardiovascular Risk In Y oung Finns Study. Ann Med 2011; 43: 312-9.
164. Tomiyama H, Hirayama Y, Hashimoto H, et al. The effects of changes in the metabolic syndrome detection status on arterial stiffening: a prospective study. Hypertens Res 2006; 29: 673-8.
165. Athyros VG, Katsiki N, Tziomalos K, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: A post hoc analysis of the GREACE study. Arch Med Sci 2013; 9: 418-26.
166. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
167. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
168. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005; 54: 1065-74.
169. Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25: 971-80.